Discover trends, market shifts, and competitive outlooks for the post-operative nausea and vomiting industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

What Is the Estimated Market Size of the Post-Operative Nausea And Vomiting Market In 2029?

The market size for post-operative nausea and vomiting has experienced considerable growth in the recent past. Predictions indicate an increase from $2.11 billion in 2024 to $2.26 billion in 2025, reflecting a compound annual growth rate (CAGR) of 7.4%. The historic growth period was influenced by factors such as increased research and development activities, a higher demand for advanced therapeutic methods, an uptick in healthcare spending, a greater emphasis on personalized medicine, and the increased uptake of digital health technologies.

Predictions point towards a steady expansion of the post-operative nausea and vomiting market over the upcoming years. The market is forecasted to reach $2.97 billion by 2029, maintaining a compound annual growth rate (CAGR) of 7.0%. Factors contributing to this projected growth include the escalating demand for pharmaceuticals, the uptake in combination therapy, heightened awareness, investments in healthcare, an expanding geriatric population, and an increasing incidence of cancer cases. The period under forecast can expect to see trends such as progressive antiemetic therapies, strategic alliances, inventive pharmaceutical formulations, the deployment of cutting-edge diagnostic tools, and the incorporation of electronic simulation devices.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=22109&type=smp

Which Major Market Drivers Are Expected to Boost the Growth Potential of the Post-Operative Nausea And Vomiting Market?

The growth of the post-operative nausea and vomiting market is expected to be driven by the increasing number of surgical procedures. Surgical operations, which involve the use of tools to identify, cure, or eliminate malfunctioning tissues or organs through cutting or manipulation, are on the rise. This surge is a result of advancements in medical technology that have made procedures safer, more effective, and less invasive, thereby increasing patient approval and broader usage. Post-operative nausea and vomiting management enhances surgical procedures by enhancing patient comfort, reducing recovery periods, lessening the likelihood of complications, ensuring more effective post-operative care, and ultimately improving overall surgical results. For example, the Australian Institute of Health and Welfare reported in November 2024 that in 2023-24, admissions for surgery from public hospital elective surgery waiting lists increased by 4.9% compared to 2022-23, with a total of 771,600 patients. Consequently, the growing number of surgical procedures is fuelling the expansion of the post-operative nausea and vomiting market.

Which Key Market Segments Comprise the Post-Operative Nausea And Vomiting Market and Drive Its Revenue Growth?

The post-operative nausea and vomiting market covered in this report is segmented –

1) By Treatment Type: Serotonin Antagonists, Steroids, Dopamine Antagonists, Neurokinin NK-1 Receptor Antagonists, Non-pharmacological Treatment, Other Treatment Types

2) By Route Of Administration: Oral, Intravenous, Transdermal, Other Route Of Administrations

3) By Patient Demographics: Pediatric Patients, Adult Patients, Geriatric Patients

4) By Surgical Procedure Type: Orthopedic Surgery, Gynecological Surgery, General Surgery, Cardiac Surgery, Ophthalmic Surgery

5) By End-User: Hospitals, Ambulatory Surgical Centers, Specialty Clinics, Other End-Users

Subsegmentss:

1) By Serotonin Antagonists Type: Ondansetron, Granisetron, Palonosetron, Dolasetron, Tropisetron

2) By Steroids Type: Dexamethasone, Methylprednisolone, Hydrocortisone, Prednisolone, Betamethasone

3) By Dopamine Antagonists Type: Metoclopramide, Droperidol, Prochlorperazine, Domperidone, Chlorpromazine

4) By Neurokinin NK-1 Receptor Antagonists Type: Aprepitant, Fosaprepitant, Rolapitant, Netupitant, Casopitant

5) By Non-Pharmacological Treatment Type: Acupressure, Aromatherapy, Hypnotherapy, Electroacupuncture, Ginger Supplements

6) By Other Treatment Types: Antihistamines, Anticholinergics, Cannabinoids, Combination Therapy, Herbal & Natural Remedies

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=22109&type=smp

Which Areas Are Leading Regions in the Post-Operative Nausea And Vomiting Market Expansion Across the Globe?

North America was the largest region in the post-operative nausea and vomiting market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the post-operative nausea and vomiting market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Are the Key Market Trends in thePost-Operative Nausea And Vomiting Market Over the Coming Years?

Leading corporations operating within the post-operative nausea and vomiting Market are concentrating on creating crucial injectable drugs with the use of advanced emulsion formulations and extended-release technology to enhance the effectiveness and extend symptom aid for patients after surgery. The term ‘critical injectable medications’ refers to vital drugs administered through injection intended to offer immediate and potent treatment for severe or critical medical situations. For instance, in July 2024, Avenacy, an American speciality pharmaceutical company, introduced Palonosetron Hydrochloride Injection in 0.25 mg/5 ml single-dose vials, aimed at assisting healthcare professionals to minimize dosage mistakes and upgrade patient safety. This injection is used for the prevention of nausea and vomiting resulting from chemotherapy and to control postoperative nausea and vomiting (PONV) for approximately 24 hours following surgery, making it a trustworthy treatment choice for patients vulnerable to these conditions.

View the full report here:

https://www.thebusinessresearchcompany.com/report/post-operative-nausea-and-vomiting-global-market-report

How Is the Post-Operative Nausea And Vomiting Market Conceptually Defined?

Post-operative nausea and vomiting (PONV) is a common complication that occurs within 24 to 48 hours after surgery, often resulting from anesthesia, pain medications, or the body’s response to surgical stress. It can significantly affect a patient’s recovery, causing discomfort, delayed healing, and an increased risk of complications like dehydration or electrolyte imbalance.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=22109

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model